Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05945563 · ClinicalTrials.gov registry record
Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 208
- Enrollment target
NCT05945563: Completed study, sponsored by Methodist Health System.
NCT05945563 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 208 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05945563 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 208 participants
- Enrollment target
Study Summary
This registry study will investigate the incidence of and outcomes associated with clopidogrel hyper-responsive patients treated at Methodist Dallas Medical Center, beginning in January 2018, who suffered cerebral aneurysms.
Primary Outcome
The demographic characteristics, treatment strategies, incidence, and outcomes in patients hyper-responsive to clopidogrel.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2025-07-18 |
What the finished NCT05945563 record still lists
NCT05945563 is an observational study that tracks outcomes without assigning an intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT05945563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05945563 about?
NCT05945563 is a clinical study titled "Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms". This registry study will investigate the incidence of and outcomes associated with clopidogrel hyper-responsive patients treated at Methodist Dallas Medical Center, beginning in January 2018, who suffered cerebral aneurysms.
What is the current status of trial NCT05945563?
This trial is currently completed. The enrollment target is 208 participants. The study started on 2023-01-17. Estimated completion is 2025-07-18.
Who is sponsoring clinical trial NCT05945563?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI